Aurobindo Pharma Limited will participate in the Trinity India 2026 – 16th Annual Global Investor Conference arranged by 360 ONE Capital on May 29, 2026. The company's officials will engage in in-person and group meetings during the event in Mumbai. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

The meeting is scheduled to take place from 09:00 AM to 06:00 PM (IST). The schedule is subject to change due to exigencies on the part of the investor or the company. The disclosure was made to the National Stock Exchange of India Limited and BSE Limited under Regulation 30.

Meeting Details

Aurobindo Pharma Limited announced that the United States Food and Drug Administration (US FDA) has classified Unit-I of its wholly owned subsidiary, Eugia Pharma Specialities Limited, as “Official Action Indicated” (OAI). The regulatory action follows an inspection of the formulation manufacturing facility situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana.

The inspection was conducted by the US FDA from February 16 to February 27, 2026. During this period, the authority identified four observations at the facility. The company received the formal communication regarding the OAI classification on May 23, 2026.

Details of the Regulatory Action

The classification of OAI signifies that regulatory officials recommend official administrative or regulatory action. This status is assigned when the inspection conditions warrant such measures. Despite the classification, the company has affirmed its commitment to maintaining the highest quality manufacturing standards across its global facilities.

Impact Assessment

In its disclosure to the stock exchanges, Aurobindo Pharma clarified that there is no impact on the company’s financials or operations as a result of this action. The company stated that it would inform the exchanges if any further information regarding the matter arises.

Inspection Summary